Antibacterial activity of a CLF nanohybrid against E. coli 949 ESBL cefotaxime-resistant bacteria via the interaction of penicillin binding protein.
No takes yet. Share an insight, caveat, or question.
Komarala et al. (2017) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: